

REMARKS

The claims are 1-3, 5, 8, 9 and 11-13. Claims 1 and 12 have been amended to more closely define applicants' invention. Claim 4 has been cancelled without prejudice or disclaimer of subject matter. Claims 1 and 12 are in independent form. Favorable reconsideration and allowance of the subject application are respectfully requested in view of the following comments.

Claims 1 and 12 have been amended to incorporate the limitations of Claim 4. Claims 1 and 12 have also been amended to indicate that the amount of sucralose in the tablet is about 0.5 to about 5 % by weight. No new matter has been introduced by these amendments.

Claims 1-5, 8, 9 and 11-13 stand rejected under 35 U.S.C. § 103(a) as allegedly being obvious over U.S. Patent No. 6,667,050 ("*Boissonneault et al.*") in view of U.S. Patent No. 3,619,292 ("*Brouillard et al.*") or *Boissonneault et al.* and U.S. Patent No. 4,684,534 ("*Valentine*") in view of *Brouillard et al.* Applicants respectfully traverse these rejections, in view of the comments set forth below.

Among the notable features of Claim 1 are the requirements that the claimed tablet include (i) about 15 to about 90% by weight of directly compressible dextrose monohydrate; (ii) about 0.5 to about 5 % by weight of sucralose, the % weight being based on the total weight of the tablet; and (iii) wherein the tablet has a weight ratio of dextrose monohydrate to sucralose of at least about 25:1.

Boissonneault et al. has been discussed previously in Applicants' response dated August 16, 2007. In column 11, Example 6 (second one labeled Example 6) discloses a 120 mg tablet, which includes 0.02 mg of sucralose and 70 mg of dextrose. On a percentage basis, there is 0.017% sucralose and 58.3% dextrose. Even if one were to substitute dextrose monohydrate

for the dextrose in the tablet, the amount would be outside the claimed range of about 0.5 to about 5 % by weight of sucralose, as set forth in Claim 1.

As such, Claim 1 is patentable over *Boissonneault et al.*

Brouillard et al. and *Valentine* also do not disclose or suggest the claimed ranges for dextrose monohydrate and sucralose set forth in Claim 1. As such, neither *Brouillard et al.* nor *Valentine* remedied the deficiencies of *Boissonneault et al.* That is neither *Brouillard et al.* nor *Valentine* disclose a tablet which includes (i) about 15 to about 90% by weight of directly compressible dextrose monohydrate; (ii) about 0.5 to about 5 % by weight of sucralose, the % weight being based on the total weight of the tablet; and (iii) wherein the tablet has a weight ratio of dextrose monohydrate to sucralose of at least about 25:1.

Therefore, Applicants respectfully submit that Claim 1 is patentable over *Boissonneault et al.*, *Brouillard et al.* and/or *Valentine*, whether considered separately or in combination.

Claim 12 is similar to Claim 1 and also includes the features of a tablet having (i) about 15 to about 90% by weight of directly compressible dextrose monohydrate; (ii) about 0.5 to about 5 % by weight of sucralose, the % weight being based on the total weight of the tablet; and (iii) wherein the tablet has a weight ratio of dextrose monohydrate to sucralose of at least about 25:1.

For at least the reasons stated above for Claim 1, Claim 12 is patentable over *Boissonneault et al.*, *Brouillard et al.* and/or *Valentine*, whether considered separately or in combination.

Claims 2, 3, 5, 8, 9 and 11 depend from Claim 1, and Claim 13 depends from Claim 12. These claims are also believed to be patentable over the cited references, since they depend from a patentable base claim.

In view of the foregoing remarks, Applicants respectfully request favorable reconsideration and allowance of the claims in the present application.

Applicants' undersigned attorney may be reached in our office by telephone at (732) 524-1767. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

/Victor Tsu, Reg. No. 46,185/

Attorney for Applicants
Victor Tsu
Registration No. 46,185

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003